Literature DB >> 7815310

Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration.

J M Cardot1, G Y Lefèvre, J A Godbillon.   

Abstract

The pharmacokinetics of recombinant hirudin (rec-hirudin, Ciba-Geigy, CGP 39,393) in healthy volunteers after iv administration was investigated on the basis of the data from five different studies. A total of 77 plasma profiles following a single iv bolus dose of either 0.1, 0.3, 0.5, or 1 mg/kg of rec-hirudin was used for the evaluation. Plasma concentrations and especially AUC were proportional to the dose. Kinetics of rec-hirudin after a bolus iv injection were best described by a three-compartment open model. Mean apparent terminal half-life was 2.8 hr and the total clearance 0.138 L/hr per kg.

Mesh:

Substances:

Year:  1994        PMID: 7815310     DOI: 10.1007/bf02353540

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  13 in total

Review 1.  Biology of recombinant hirudin (CGP 39393): a new prospect in the treatment of thrombosis.

Authors:  M Talbot
Journal:  Semin Thromb Hemost       Date:  1989-07       Impact factor: 4.180

Review 2.  Pharmacokinetics of hirudin.

Authors:  G Nowak
Journal:  Semin Thromb Hemost       Date:  1991-04       Impact factor: 4.180

Review 3.  The comeback of hirudin--an old-established anticoagulant agent.

Authors:  F Markwardt
Journal:  Folia Haematol Int Mag Klin Morphol Blutforsch       Date:  1988

4.  A hirudin catching ELISA for quantitating the anticoagulant in biological fluids.

Authors:  S Spinner; F Scheffauer; R Maschler; G Stöffler
Journal:  Thromb Res       Date:  1988-09-15       Impact factor: 3.944

5.  Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration.

Authors:  J Bichler; B Fichtl; M Siebeck; H Fritz
Journal:  Arzneimittelforschung       Date:  1988-05

6.  Clinico-pharmacological studies with recombinant hirudin.

Authors:  F Markwardt; G Nowak; J Stürzebecher; G Vogel
Journal:  Thromb Res       Date:  1988-12-01       Impact factor: 3.944

7.  Pharmacokinetics and anticoagulant effect of hirudin in man.

Authors:  F Markwardt; G Nowak; J Stürzebecher; U Griessbach; P Walsmann; G Vogel
Journal:  Thromb Haemost       Date:  1984-10-31       Impact factor: 5.249

8.  Pharmacological studies on the antithrombotic action of hirudin in experimental animals.

Authors:  F Markwardt; J Hauptmann; G Nowak; C Klessen; P Walsmann
Journal:  Thromb Haemost       Date:  1982-06-28       Impact factor: 5.249

9.  Clinical pharmacology of recombinant hirudin.

Authors:  F Markwardt; G Nowak; J Stürzebecher
Journal:  Haemostasis       Date:  1991

10.  Pharmacological survey of recombinant hirudin.

Authors:  F Markwardt; G Fink; B Kaiser; H P Klöcking; G Nowak; M Richter; J Stürzebecher
Journal:  Pharmazie       Date:  1988-03       Impact factor: 1.267

View more
  1 in total

1.  Desirudin: a review of its use in the management of thrombotic disorders.

Authors:  A J Matheson; K L Goa
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.